comparemela.com

Latest Breaking News On - Andrew schwendenman - Page 1 : comparemela.com

Form 10-K Replimune Group, Inc. For: Mar 31

Form 10-K Replimune Group, Inc. For: Mar 31
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong-kong
United-states
Massachusetts
Israel
Washington
Delaware
California
Oxfordshire
United-kingdom
China
Ukraine
Russia

Form 8-K Replimune Group, Inc. For: May 18

Form 8-K Replimune Group, Inc. For: May 18
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Washington
United-states
Delaware
Andrew-schwendenman
Philip-astley-sparke
Jean-franchi
Business-administration
Securities-exchange
Board-of-directors-the-company
Life-sciences
Replimune-group-inc
Nasdaq-stock-market

Form S-8 Replimune Group, Inc.

Form S-8 Replimune Group, Inc.
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Washington
United-states
Boston
Massachusetts
Delaware
Commonwealth-of-massachusetts
Joseph-slattery
Sander-slootweg
Hyam-levitsky
Dieter-weinand
Christopher-sarchi
Jean-franchi

Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update

18.05.2023 - Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo (cemiplimab-rwlc) in cutaneous squamous cell carcinoma (CSCC) on track for Q3 2023 and Biologics License Application (BLA) submission on track .

United-states
American
Arleen-goldenberg
Bristol-myers-squibb
Chris-brinzey
Jean-franchi
Philip-astley-sparke
Andrew-schwendenman
Program-highlights-milestones
American-transplant-congress
Exchange-commission
Securities-exchange

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.